U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT07476066) titled 'Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory Aggressive B-Cell Lymphoma' on March 04.
Brief Summary: This is a Phase I/II clinical study conducted in participants with relapsed/refractory aggressive B-cell lymphoma. The study aims to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SYS6055 Injection in participants with relapsed/refractory aggressive B-cell lymphoma, and to provide a basis for the recommended dosing regimen in subsequent studies.
Study Start Date: March 15
Study Type: INTERVENTIONAL
Condition:
Relapsed/Refractory Aggressive B-Cell Lym...